HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

Benzinga · 2d ago
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.